XBiotech Inc.
corporate_fare Company Profile
XBiotech Inc. (NASDAQ:XBIT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for XBIT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for XBIT spans 4, 8-K, 10-K/A, 10-K.
Recent high-impact activity:
- Founder/Director John Simard Buys 368,524 XBIT Shares for $711,251 From Thorpe McKenzie
- XBiotech Names Founder's 24-Year-Old Son Co-CEO With 2M Option Grant
- Phase II TASKIN Data Show 61.3% 12-Month Survival in Refractory Colorectal Cancer
- XBiotech's Vilamakitug Advances to Phase II for Spondyloarthritis After FDA Clearance
- XBiotech Discloses $30M Payout to Former CEO, Details New Equity Plan in Amended 10-K
Financial Snapshot
Short Interest & Short Volume
2.64 days to coverFINRA reported short interest of 315,307 shares in XBIT as of the October 30, 2026 settlement, a 4.8% increase from the prior period — about 2.6 days to cover at its recent average daily volume. On November 20, 2026, 50.6% of XBIT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.